Presentation
15 February 2021 Preclinical in vivo x-ray fluorescence computed tomography
Author Affiliations +
Abstract
X-ray fluorescence computed tomography (XFCT) with nanoparticles (NPs) as contrast agents has reached technical maturity allowing for in vivo preclinical imaging in the laboratory setting. We present the first in vivo longitudinal study with XFCT where mice were 5 times each during an 8-week period. Imaging is performed with low radiation dose (<25 mGy) and high signal-to-background for high-spatial-resolution imaging (200-400 µm) of molybdenum NP accumulations (down to ~50 µg/ml Mo). We further discuss our ongoing development of protein-coated NPs for actively targeting molecular markers (e.g., cancer), as well as potential clinical applications.
Conference Presentation
© (2021) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Kian Shaker, Carmen Vogt, Yurika Katsu-Jimenéz, Raoul V. Kuiper, Kenth Andersson, Yuyang Li, Jakob C. Larsson, Aida Rodriguez-Garcia, Muhammet S. Toprak, Marie Arsenian-Henriksson, and Hans M. Hertz "Preclinical in vivo x-ray fluorescence computed tomography", Proc. SPIE 11595, Medical Imaging 2021: Physics of Medical Imaging, 115951O (15 February 2021); https://doi.org/10.1117/12.2580858
Advertisement
Advertisement
KEYWORDS
Nanoparticles

X-ray fluorescence spectroscopy

Computed tomography

In vivo imaging

Gold

Molybdenum

Fluorescence tomography

Back to Top